Tazemetostat was recently evaluated in combination with the PD-L1 blocker atezolizumab for the treatment of relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL), with tolerable safety but only modest antitumor activity reported (objective response rate [ORR] 16%) (15). The gene discussed is CD274; the disease is diffuse large B-cell lymphoma.